Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
34.15
+0.14 (0.41%)
May 3, 2024, 4:00 PM EDT - Market closed
Inhibrx Revenue
In the year 2023, Inhibrx had annual revenue of $1.80M, a decrease of -17.88%. Revenue in the quarter ending December 31, 2023 was $1.63M with 496.35% year-over-year growth.
Revenue (ttm)
$1.80M
Revenue Growth
-17.88%
P/S Ratio
899.14
Revenue / Employee
$10,465
Employees
172
Market Cap
1.62B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
Dec 31, 2018 | 8.60M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.06B |
Myriad Genetics | 753.20M |
Tilray Brands | 743.25M |
Harmony Biosciences Holdings | 617.51M |
Taro Pharmaceutical Industries | 610.83M |
Supernus Pharmaceuticals | 607.52M |
Beam Therapeutics | 377.71M |
Zai Lab | 266.72M |
INBX News
- 2 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PRNewsWire
- 3 months ago - INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX - Business Wire
- 3 months ago - Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi - PRNewsWire
- 3 months ago - Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline - Investopedia
- 3 months ago - INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders - Business Wire
- 3 months ago - Sanofi to Buy Rare-Disease Assets From Inhibrx - WSJ
- 3 months ago - France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln - Reuters
- 3 months ago - Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline - GlobeNewsWire